Form 4: IMMUNIC President and COO Acquires Over 2.3 Million Stock Appreciation Rights

IMMUNIC, Inc.'s President and COO, Jason Tardio, acquired 2,310,000 Stock Appreciation Rights with an exercise price of $0.77, exercisable from August 1, 2026, subject to various conditions including warrant exercises and private placement tranches.

Summary

• Jason Tardio, President and COO of IMMUNIC, INC. (IMUX), acquired a total of 2,310,000 Stock Appreciation Rights (SARs) on July 16, 2025.
• The SARs have an exercise price of $0.77 per share and expire on July 16, 2035.
• All SARs become exercisable beginning August 1, 2026.
• The exercisability of 330,000 SARs is subject to the exercise of the Issuer's series A purchase warrants.
• The exercisability of 660,000 SARs is subject to the exercise of the Issuer's series B purchase warrants.
• The exercisability of 330,000 SARs is subject to the Issuer's issuance of Common Stock or pre-funded warrants in connection with the second tranche of the January 4, 2024 private placement.
• The exercisability of another 330,000 SARs is subject to the Issuer's issuance of Common Stock or pre-funded warrants in connection with the third tranche of the January 4, 2024 private placement.
• The SARs are intended to be settled in shares of IMMUNIC's common stock, contingent on obtaining stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to provide sufficient shares.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The acquisition of SARs by a key executive is generally a positive signal of confidence in future stock performance. However, the conditional nature of their exercisability introduces some uncertainty, slightly tempering the overall positive sentiment.

Positives

• The acquisition of a significant number of Stock Appreciation Rights by a key executive like the President and COO indicates management's confidence in the future performance and stock price appreciation of IMMUNIC, INC.
• The SARs align the executive's incentives with shareholder value creation, as their value increases with the company's stock price above the $0.77 exercise price.

Negatives

• The exercisability of the SARs is subject to several conditions, including the exercise of specific warrants and the completion of future tranches of a private placement, which introduces uncertainty regarding the timing and certainty of the executive's ability to realize value from these rights.
• The settlement of SARs in common stock is contingent on obtaining stockholder approval to amend the 2019 Omnibus Equity Incentive Plan, which is not guaranteed.

Risks

• The ability to exercise the Stock Appreciation Rights is contingent on the exercise of the Issuer's series A and series B purchase warrants by their respective holders.
• The ability to exercise a portion of the Stock Appreciation Rights is contingent on the Issuer's successful issuance of Common Stock or pre-funded warrants related to the second and third tranches of the January 2024 private placement.
• The intended settlement of SARs in common stock rather than cash is subject to obtaining stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to ensure sufficient shares are available.

Future Outlook

The future outlook for the value of these Stock Appreciation Rights is tied to the company's stock price performance above the $0.77 exercise price. The successful completion of the remaining tranches of the January 2024 private placement and the exercise of outstanding warrants are key factors influencing the exercisability of these SARs.

Industry Context

This Form 4 filing reflects a common practice in the biotechnology or pharmaceutical industry where executive compensation often includes equity-linked incentives like Stock Appreciation Rights to align management interests with long-term shareholder value. The reliance on warrant exercises and private placement tranches for SAR exercisability suggests ongoing capital-raising activities and strategic financing efforts, which are typical for development-stage biotech companies like IMMUNIC, Inc.

Comparison to Industry Standards

• The grant of Stock Appreciation Rights with a 10-year expiration period and an exercise price at the market value ($0.77) is a standard practice for long-term executive incentives in the biotechnology and pharmaceutical sectors.
• While the specific conditions for exercisability tied to warrant exercises and private placement tranches are less common, they reflect the unique financing strategies often employed by development-stage biotech companies like IMMUNIC, Inc., which frequently rely on capital raises to fund operations and clinical development, unlike more established, revenue-generating industry peers.
• No specific comparable companies or projects are mentioned in the filing to provide a direct benchmark.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution if SARs are settled in stock and the equity plan is amended. However, the grant aligns executive incentives with shareholder value.
• Employees: The grant of SARs to a key executive sets a precedent for executive compensation structure.

Next Steps

• IMMUNIC, Inc. needs to obtain stockholder approval to amend its 2019 Omnibus Equity Incentive Plan to provide sufficient shares for the settlement of SARs in common stock.
• The company needs to complete the issuance of Common Stock or pre-funded warrants related to the second and third tranches of the January 2024 private placement.
• Holders of the Issuer's series A and series B purchase warrants need to exercise their warrants for the related SARs to become exercisable.

Key Dates

Recommendation

Keywords

IMMUNIC, IMUX, Stock Appreciation Rights, SARs, Insider Trading, Executive Compensation, Form 4, SEC Filing, Equity Incentive Plan, Private Placement, Warrants